DC biosciences provides pharmaceutical and biotech companies with novel technologies and proteomics services to support the development of safer drugs faster.
We are best placed to apply our knowledge and experience in a wide range of bioscience disciplines including quantitative proteomics, chemical biology, biochemistry, molecular biology, bioinformatics and cell biology to provide solutions in key areas of drug discovery and development.
We have developed a quantitative proteomics-based technology portfolio that offers solutions to preclinical activities of the drug discovery process and developed new processes for biomarker discovery and validation, drug re-profiling and repositioning.